University of Michigan, Kura Oncology deal

Last December, the university granted Kura exclusive, worldwide rights to a class of preclinical small molecule inhibitors targeting menin-MLL fusion oncogene, including MI-463 and MI-503. Preclinical data published in Cancer Cell and Nature Medicine showed that MI-463 and MI-503 block progression of mixed lineage acute leukemias and castration-resistant prostate cancer (CRPC) in mice. ...